Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance study of oral [14C]-PBI-4050 in healthy male volunteers
NL-OMON46181Active, not recruiting
- Sponsor
- Liminal BioSciences Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fezagepras in fibrosis, sponsored by Liminal BioSciences Inc. Primary endpoints: [14C]-radioactivity in plasma and whole blood, Blood cell/plasma ratio of [14C]-radioactivity and 21 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
fezagepras
03
Conditions
fibrosis
Beyond the preview
Go deeper on NL-OMON46181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46181.